Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/1b, Open-label Multi-center Two-part Study of SETD2 Inhibitor EZM0414 in Subjects With Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Diffuse Large B Cell Lymphoma

NCT05121103 is registered in ClinicalTrials.gov with Epizyme, Inc. as lead sponsor.

NCT NCT05121103
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05121103 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/1b, Open-label Multi-center Two-part Study of SETD2 Inhibitor EZM0414 in Subjects With Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Diffuse Large B Cell Lymphoma
Lead sponsor
Epizyme, Inc.
Phase
Phase 1
Overall status
Terminated
Start date
May 31, 2022
Completion date
April 30, 2024
Enrollment
13 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

diffuse large b cell lymphoma refractory, diffuse large b-cell lymphoma, multiple myeloma in relapse, multiple myeloma, refractory